Apollon Wealth Management LLC Has $40.96 Million Position in Johnson & Johnson $JNJ

Key Points

• Apollon Wealth Management increased its Johnson & Johnson stake by 20.3% in the second quarter, bringing its holdings to 161,278 shares valued at approximately $40.96 million. Institutional investors own 69.55% of JNJ.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $268.22; recent targets range as high as $294.
• Johnson & Johnson exceeded quarterly earnings and revenue estimates, reporting $2.90 EPS and $25.31 billion in revenue, while declaring a quarterly dividend of $1.34, or $5.36 annually, yielding about 2.0%.

Apollon Wealth Management LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 20.3% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 161,278 shares of the company's stock after acquiring an additional 27,192 shares during the period. Apollon Wealth Management LLC's holdings in Johnson & Johnson were worth $40,960,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Blueline Advisors LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $25,000. Cresta Advisors Ltd. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. DecisionPoint Financial LLC lifted its stake in shares of Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock worth $30,000 after buying an additional 75 shares during the last quarter. Bay Harbor Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock worth $31,000 after buying an additional 49 shares during the period. Finally, Semmax Financial Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after buying an additional 72 shares during the period. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a report on Monday, August 3rd. Morgan Stanley raised their price target on Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research report on Thursday, July 16th. Wall Street Zen lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, Guggenheim boosted their price objective on Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $268.22.

Insider Buying and Selling

In related news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares of the company's stock, valued at $4,367,458. This trade represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares of the company's stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 48,972 shares of company stock valued at $12,295,205 over the last three months. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Up 0.8%

Shares of JNJ stock opened at $262.43 on Tuesday. The firm has a market capitalization of $632.43 billion, a P/E ratio of 30.41, a price-to-earnings-growth ratio of 2.48 and a beta of 0.24. Johnson & Johnson has a 1 year low of $173.33 and a 1 year high of $274.90. The firm's fifty day simple moving average is $252.52 and its 200 day simple moving average is $241.60. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business's revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is presently 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source